Kairos Pharma, Stock Market Value
| KAPA Stock | 0.74 0.01 1.33% |
| Symbol | Kairos |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kairos Pharma,. If investors know Kairos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kairos Pharma, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kairos Pharma, is measured differently than its book value, which is the value of Kairos that is recorded on the company's balance sheet. Investors also form their own opinion of Kairos Pharma,'s value that differs from its market value or its book value, called intrinsic value, which is Kairos Pharma,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kairos Pharma,'s market value can be influenced by many factors that don't directly affect Kairos Pharma,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kairos Pharma,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Kairos Pharma, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kairos Pharma,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Kairos Pharma, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Kairos Pharma,'s stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Kairos Pharma,.
| 06/28/2025 |
| 12/25/2025 |
If you would invest 0.00 in Kairos Pharma, on June 28, 2025 and sell it all today you would earn a total of 0.00 from holding Kairos Pharma, or generate 0.0% return on investment in Kairos Pharma, over 180 days. Kairos Pharma, is related to or competes with Lixte Biotechnology, Pelthos Therapeutics, Lexaria Bioscience, CASI Pharmaceuticals, Allarity Therapeutics, Cingulate, and Briacell Therapeutics. More
Kairos Pharma, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Kairos Pharma,'s stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Kairos Pharma, upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.1) | |||
| Maximum Drawdown | 24.3 | |||
| Value At Risk | (10.62) | |||
| Potential Upside | 9.41 |
Kairos Pharma, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kairos Pharma,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Kairos Pharma,'s standard deviation. In reality, there are many statistical measures that can use Kairos Pharma, historical prices to predict the future Kairos Pharma,'s volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.71) | |||
| Total Risk Alpha | (1.05) | |||
| Treynor Ratio | (0.14) |
Kairos Pharma, Backtested Returns
Kairos Pharma, has Sharpe Ratio of -0.0818, which conveys that the firm had a -0.0818 % return per unit of risk over the last 3 months. Kairos Pharma, exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Kairos Pharma,'s Mean Deviation of 4.43, standard deviation of 5.7, and Risk Adjusted Performance of (0.05) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 3.35, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Kairos Pharma, will likely underperform. At this point, Kairos Pharma, has a negative expected return of -0.47%. Please make sure to verify Kairos Pharma,'s treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Kairos Pharma, performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.63 |
Very good reverse predictability
Kairos Pharma, has very good reverse predictability. Overlapping area represents the amount of predictability between Kairos Pharma, time series from 28th of June 2025 to 26th of September 2025 and 26th of September 2025 to 25th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Kairos Pharma, price movement. The serial correlation of -0.63 indicates that roughly 63.0% of current Kairos Pharma, price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.63 | |
| Spearman Rank Test | -0.65 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
Kairos Pharma, lagged returns against current returns
Autocorrelation, which is Kairos Pharma, stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Kairos Pharma,'s stock expected returns. We can calculate the autocorrelation of Kairos Pharma, returns to help us make a trade decision. For example, suppose you find that Kairos Pharma, has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Kairos Pharma, regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Kairos Pharma, stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Kairos Pharma, stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Kairos Pharma, stock over time.
Current vs Lagged Prices |
| Timeline |
Kairos Pharma, Lagged Returns
When evaluating Kairos Pharma,'s market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Kairos Pharma, stock have on its future price. Kairos Pharma, autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Kairos Pharma, autocorrelation shows the relationship between Kairos Pharma, stock current value and its past values and can show if there is a momentum factor associated with investing in Kairos Pharma,.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kairos Pharma, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kairos Pharma,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kairos Pharma, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kairos Pharma, Stock:Check out Kairos Pharma, Correlation, Kairos Pharma, Volatility and Kairos Pharma, Alpha and Beta module to complement your research on Kairos Pharma,. For information on how to trade Kairos Stock refer to our How to Trade Kairos Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Kairos Pharma, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.